Assessment of Tear Film Thickness by Optical Coherence Tomography in Healthy Subjects and Subjects With Dry Eye Disease

Last updated: November 13, 2014
Sponsor: Medical University of Vienna
Overall Status: Trial Not Available

Phase

3

Condition

Sjogren's Syndrome

Eye Disease

Eyelid Inflammation

Treatment

N/A

Clinical Study ID

NCT01753596
OPHT-200612
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Dry eye syndrome (DES) is a highly prevalent ocular condition with severe consequences for the patients reaching from ocular discomfort in its simplest form up to visual impairment and corneal ulceration in severe cases. Data from epidemiological studies indicate that DES is a common disease, especially in the elderly population, affecting up to 20% of adults aged 45 years or older. Topical lubricants are a mainstay of therapy, but data on its effect on tear film thickness and the corneal residence time are lacking.

Recently, a new objective method for assessment of tear film thickness by optical coherence tomography has been developed. The present study aims to investigate the corneal residence time of an established topical lubricant compared to placebo in patients with DES and healthy controls.

Eligibility Criteria

Inclusion

Inclusion Criteria: Inclusion criteria for healthy subjects:

  • Men and women aged over 18 years

  • Normal findings in the medical history unless the investigator considers anabnormality to be clinically irrelevant

  • Normal ophthalmic findings, ametropia < 6 Dpt

  • Schirmer I test > 10 mm and BUT > 10 sec Inclusion criteria for patients with dry eye syndrome:

  • Men and women aged over 18 years

  • Normal findings in the medical history unless the investigator considers anabnormality to be clinically irrelevant except DES

  • Normal ophthalmic findings, ametropia < 6 Dpt

  • History of dry eye syndrome for at least 3 months

  • Tear Break Up Time (BUT) < 10 seconds or Schirmer I test < 7 mm

  • At least 2 symptoms of dry eye syndrome (foreign body sensation, burning, photophobia,blurred vision, pain, itching)

  • Normal ophthalmic findings except dry eye syndrome

Exclusion

Exclusion Criteria:

  • Regular use of medication (except contraceptives), abuse of alcoholic beverages,participation in a clinical trial in the 3 weeks preceding the study

  • Treatment in the previous 3 weeks with any drug

  • Symptoms of a clinically relevant illness in the 3 weeks before the first study day

  • Ametropia >= 6 Dpt

  • Pregnancy

  • Difference of more than 3 mm in Schirmer I test or difference of > 3 sec in BUTbetween the two eyes

  • Known medical history of allergy, hypersensitivity or poor tolerance to any componentsof the medication or medical product used in the study

Study Design

Study Start date:
December 01, 2014
Estimated Completion Date:
February 28, 2015

Connect with a study center

  • Department of Clinical Pharmacology, Medical University of Vienna

    Vienna, 1090
    Austria

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.